2021
DOI: 10.1101/2021.06.17.448569
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer

Abstract: Purpose: Radioligand therapy (RLT) is relatively unexplored in metastatic castration resistant prostate cancer (mCRPC), with much of the focus having been on bone seeking radionuclides and PSMA-directed RLT. Herein, we evaluated if CUB domain containing protein 1 (CDCP1) can be exploited to treat mCRPC with RLT, particularly for subsets like small cell neuroendocrine prostate cancer (SCNC) that would not be expected to respond to current options. Experimental Design: CDCP1 mRNA levels were evaluated in the R… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 26 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?